Skip to content
Recall Observatory FDA recall evidence

Drug product

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-746-05

D-0271-2025

February 28, 2025

Class II

Product summary

Firm
Breckenridge Pharmaceutical, Inc.
Event
Event 96380
Status
Ongoing
Classification
Class II
Quantity
11,125 bottles.
Official record key
drug-enforcement:D-0271-2025

Official wording

Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Code information: Lot#: 240098C, Expiration: 01/2027.

Distribution pattern: Nationwide

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    N-nitroso-duloxetine impurity
  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations